Differential Characteristics of Human Airway Organoids at Different Stages of Differentiation After Respiratory Syncytial Virus Infection

LUO Jiaxin, YANG Wenhao, HU Yanan, LU Danli, CHEN Lina, LIU Hanmin

Abstract

To investigate the differences in pathological changes and immune responses of human airway organoids at different stages of differentiation following respiratory syncytial virus (RSV) infection.

Methods 

Models of human fetal lung organoids (FLO) and induced airway organoids (iAO) were established to simulate immature and mature airway epithelium. Immunofluorescence staining, electron microscopy, and quantitative polymerase chain reaction (Q-PCR) were used to confirm the successful construction of the lung organoid models. Human lung organoids were infected with RSV, and samples were collected at 6 and 48 hours post-infection. The immune characteristics of immature and mature RSV-infected organoids were assessed using immunofluorescence staining, droplet digital PCR (DDPCR), and Q-PCR.

Results 

We successfully generated FLO expressing both the progenitor markers sex determining region Y-box transcription factor 2 (SOX2) and sex determining region Y-box transcription factor 9 (SOX9), as well as iAO containing basal cells, ciliated cells, club cells, and goblet cells. In addition, organoid models of RSV infection were established. DDPCR results showed that, at the initial stage of RSV infection, the viral load in iAO was significantly higher than that in FLO (P < 0.001). However, at 48 hours post-infection, the viral load in iAO was lower than that in FLO (P < 0.05). Q-PCR results indicated that the expression of RSV infection receptor genes, including epidermal growth factor receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R), and nucleolin (NCL), was significantly higher in iAO compared to that in FLO (P < 0.001). RSV infection led to an increase in the expression levels of immune factors, including interleukin 6 (IL-6), interleukin 8 (CXCL8), interferon α (IFN-α), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor α (TNF-α), in iAO compared to those in FLO, and the differences were statistically significant (P < 0.05).

Conclusion 

The expression of RSV infection receptor proteins increases with airway maturation, and mature airway epithelial cells exhibit a stronger immune response than immature ones do, effectively inhibiting RSV replication.

 

Keywords: Respiratory syncytial virus, Organoids, Antiviral effect

 

Full Text:

PDF


References


SHI T, MCALLISTER D A, O'BRIEN K L, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet, 2017, 390(10098): 946-958. doi: 10. 1016/s0140-6736(17)30938-8.

SMITH D K, SEALES S, BUDZIK C. Respiratory syncytial virus bronchiolitis in children. Am Fam Physician, 2017, 95(2): 94-99.

ZHANG S, AKMAR L Z, BAILEY F, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. J Infect Dis, 2020, 222(Suppl 7): S680-s687. doi: 10.1093/infdis/jiz683.

PIEDIMONTE G, PEREZ M K. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev, 2014, 35(12): 519-530.

CHEN Y, WANG H X. Clinical development and evaluation of human respiratory syncytial virus vaccines. Chin J New Drugs, 2025, 34(01): 43-51. doi: 10.20251/j.cnki.1003-3734.2025.01.007.

FONSECA W, LUKACS N W, PTASCHINSKI C. Factors affecting the immunity to respiratory syncytial virus: from epigenetics to microbiome. Front Immunol, 2018, 9: 226. doi: 10.3389/fimmu.2018.00226.

RESCH B. Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr, 2012, 1(3): 8-12. doi: 10.5409/wjcp.v1.i3.8.

KORPPI M, PIIPPO-SAVOLAINEN E, KORHONEN K, et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol, 2004, 38(2): 155-160. doi: 10.1002/ppul.20058.

VILLENAVE R, THAVAGNANAM S, SARLANG S, et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A, 2012, 109(13): 5040-5045. doi: 10.1073/pnas.1110203109.

PIEDIMONTE G, WALTON C, SAMSELL L. Vertical transmission of respiratory syncytial virus modulates pre- and postnatal innervation and reactivity of rat airways. PLoS One, 2013, 8(4): e61309. doi: 10.1371/journal.pone.0061309.

KIM J, KOO B K, KNOBLICH J A. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol, 2020, 21(10): 571-584. doi: 10.1038/s41580-020-0259-3.

HIRABARA S M, SERDAN T D A, GORJAO R, et al. SARS-COV-2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol, 2021, 11: 781429. doi: 10.3389/fcimb.2021.781429.

HUFF S, KUMMETHA I R, TIWARI S K, et al. Discovery and mechanism of SARS-CoV-2 main protease inhibitors. J Med Chem, 2022, 65(4): 2866-2879. doi: 10.1021/acs.jmedchem.1c00566.

ZIEGLER C G K, ALLON S J, NYQUIST S K, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell, 2020, 181 (5): 1016-1035. e19. doi:10.1016/j.cell.2020.04.035.

MILLER A J, YU Q, CZERWINSKI M, et al. In vitro and in vivo development of the human airway at single-cell resolution. Dev Cell, 2020, 54(6): 818. doi: 10.1016/j.devcel.2020.09.012.

RACKLEY C R, STRIPP B R. Building and maintaining the epithelium of the lung. J Clin Invest, 2012, 122(8): 2724-2730. doi: 10.1172/jci60519. SCHITTNY J C. Development of the lung. Cell Tissue Res, 2017, 367(3): 427-444. doi: 10.1007/s00441-016-2545-0.

DENG W, XIE X, CHENG Q, et al. Use of organoids in infectious disease modeling. Chin J Cell Biol, 2024, 46(02): 365-372. doi: 10.11844/cjcb. 2024.02.0019.

WEN X, MO S, CHEN S, et al. Pathogenic difference of respiratory syncytial virus infection in cotton rats of different ages. Microb Pathog, 2019, 137: 103749. doi: 10.1016/j.micpath.2019.103749.

ZEPP J A, MORRISEY E E. Cellular crosstalk in the development and regeneration of the respiratory system. Nat Rev Mol Cell Biol, 2019, 20(9): 551-566. doi: 10.1038/s41580-019-0141-3.

RAYAVARA K, KUROSKY A, HOSAKOTE Y M. Respiratory syncytial virus infection induces the release of transglutaminase 2 from human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2022, 322(1): L1-L12. doi: 10.1152/ajplung.00013.2021.

MLCOCHOVA P, KEMP S A, DHAR M S, et al. SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion. Nature, 2021, 599 (7883): 114-119. doi:10.1038/s41586-021-03944-y.

LAMERS M M, Van der VAART J, KNOOPS K, et al. An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type Ⅱ-like cells. EMBO J, 2021, 40(5): e105912. doi: 10.15252/embj.2020105912.

SUN B W, ZHANG P P, WANG Z H, et al. Prevention and potential treatment strategies for respiratory syncytial virus. Molecules, 2024, 29(3): 598. doi:10.3390/molecules29030598.

JORQUERA P A, MATHEW C, PICKENS J, et al. Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro. J Virol, 2019, 93(4): e01684-18. doi:10.1128/jvi.01684-18.

CURRIER M G, LEE S, STOBART C C, et al. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression. PLoS Pathog, 2016, 12(5): e1005622. doi: 10.1371/journal.ppat.1005622.

TAYYARI F, MARCHANT D, MORAES T J, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med, 2011, 17(9): 1132-1135. doi: 10.1038/nm.2444.

GRIFFITHS C D, BILAWCHUK L M, MCDONOUGH J E, et al. IGF1R is an entry receptor for respiratory syncytial virus. Nature, 2020, 583(7817): 615-619. doi: 10.1038/s41586-020-2369-7.

HOFFMANN F, ALBERT M H, ARENZ S, et al. Intracellular T-cell cytokine levels are age-dependent in healthy children and adults. Eur Cytokine Netw, 2005, 16(4): 283-288.

THORNHILL E M, VERHOEVEN D. Respiratory syncytial virus's non-structural proteins: masters of interference. Front Cell Infect Microbiol, 2020, 10: 225. doi: 10.3389/fcimb.2020.00225.

CHURISO G, HUSEN G, BULBULA D, et al. Immunity cell responses to RSV and the role of antiviral inhibitors: a systematic review. Infect Drug Resist, 2022, 15: 7413-7430. doi: 10.2147/idr.S387479.

SOUKUP J M, BECKER S. Role of monocytes and eosinophils in human respiratory syncytial virus infection in vitro. Clin Immunol, 2003, 107(3): 178-185. doi: 10.1016/s1521-6616(03)00038-x.


Refbacks

  • There are currently no refbacks.